TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female aged 6-12 years~* females of Child-bearing Potential (FOCP) must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline.~* a primary diagnosis of ADHD based on a detailed psychiatric evaluation~* a total score of =\>26 on the ADHD-RS-IV at the Baseline Visit~* a minimum level of intellectual functioning, as determined by an IQ (based on KBIT) score of 80 or above~* no comorbid illness that could affect safety or tolerability or in any way interfere with the subject's participation in the study.~EXCLUSION CRITERIA:~* a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis (except ODD) with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder~* a known non-responder to psychostimulant treatment~* overweight (Body Mass Index (BMI)-for-age \>90th percentile)~* a history of seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.~* Conduct Disorder.~* Subject has taken an investigational drug within 30 days prior to Screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebp matching MTS and Concerta for 7 weeks
- Concerta (Type: ACTIVE_COMPARATOR): Methylphenidate HCL 18mg tablet 7 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 or more including following conditions~  * Family history of gastric cancer~ * Post endoscopic resection status for early gastric cancer or adenoma~ * Peptic ulcer disease (benign gastric ulcer and duodenal ulcer)~ * Chronic gastritis~ * Non-ulcer dyspepsia~ * Healthy adults who want to receive H. pylori treatment~* H. pylori positive by urea breath test, histology, or rapid urease test~Exclusion Criteria:~* History of H. pylori eradication therapy~* History of stomach operation~* Other organ cancer within 5 years~* Liver cirrhosis or Hepatic insufficiency~* Renal insufficiency~* Current treatment for serious medical condition which may hinder participation~* Contraindication or allergy history for H. pylori treatment regimens~* Mental incompetence to understand and sign informed consent~* Incompatible conditions to be included into the trial by investigators' decision~* Inability to provide an informed consent~* History of treatment for peptic ulcer disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard triple therapy (Type: ACTIVE_COMPARATOR): 7 day-PPI based standard triple therapy
- Bismuth quadruple therapy (Type: ACTIVE_COMPARATOR): 10 day-bismuth quadruple therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation~* Participant meets Adult Treatment Panel (ATP) III High Risk criteria~Exclusion Criteria:~* Females who are pregnant or breastfeeding~* Participant consumes more than 14 alcoholic beverages per week~* Participant has been treated with an investigational drug within the last 30 days~* Participant has congestive heart failure (New York Heart Association \[NYHA\] Type III or IV)~* Participant has had gastric bypass~* Participant is newly diagnosed with type 1 or 2 diabetes~* Participant is Human Immunodeficiency Virus (HIV) positive~* Participant has a history of drug or alcohol abuse within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ezetimibe/simvastatin 10/40 (Type: EXPERIMENTAL): Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
- atorvastatin 40 mg (Type: ACTIVE_COMPARATOR): Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advancing Tobacco Use Treatment for African American Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identified African American~* Smokes ≥ 1 cigarette per day (cpd)~* Smoke on ≥ 25 days of the past 30 days~* Functioning telephone~* Interested in quitting smoking~* Interested in taking 3 months of varenicline~* Willing to complete all study visits~Exclusion Criteria:~* Renal impairment~* Evidence or history of clinically significant allergic reactions to varenicline~* A cardiovascular event in the past month~* History of alcohol or drug dependence in the past year~* Major depressive disorder in the last year requiring treatment~* History of panic disorder, psychosis, bipolar disorder, or eating disorders~* Use of tobacco products other than cigarettes in past 30 days~* Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline~* Pregnant, contemplating getting pregnant, or breastfeeding~* Plans to move from Kansas City during the treatment and follow-up phase~* Another household member enrolled in the study~* Evidence of current severe major depressive disorder or suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chantix (varenicline) (Type: EXPERIMENTAL): Participants will receive 1mg pills to take twice a day for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a placebo pill to take twice a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients diagnosed with (primary or secondary) Myelodysplastic Syndrome including chronic myelomonocytic leukemia (CMML) with an International Prognostic Scoring System more than or equal to Interferon-1~* Patients who have never treated with hypomethylating agent (azacitidine and decitabine)~* Female patients who are postmenopausal or received contraceptive operation or refrain from sexual relations.~* Women of childbearing potential should conduct an effective method of birth control as defined in protocol, in case of male patients who will not have a baby within 2 months after the completion of decitabine therapy~Exclusion Criteria:~* Patients diagnosed with acute myelogenous leukemia (bone marrow stem cell counts exceeding 20 %) or other progressive malignant diseases~* Patients with active infection of virus or bacteria~* Patients who used to be treated with azacitidine or decitabine~* Patients who are hypersensitive to excipients of decitabine~* Patients who are pregnant and breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject provides written informed consent and HIPAA authorization before any study procedures are conducted~2. Subject is female~3. Subject is aged 21-80 years~4. Subject has a body mass index (BMI) \< 37 kg/m2~5. Subject is menopausal either naturally (at least 12 months amenorrheic) or 6 weeks after a bilateral salpingo-oophorectomy prior to natural menopause subjects with hysterectomy only must have a serum Follicle Stimulating Hormone \> 40 milli-International unit /mL~6. Subject has vulvovaginal atrophy with dyspareunia~7. Subject has had a normal mammogram within the last 6 months~8. Subject has normal pap smear within last 6 months~9. Subject has an endometrial stripe ≤ 4 mm within the last 6 months if she has a uterus~10. Subject agrees to comply with the study procedures and visits.~Exclusion Criteria:~1. Subject has a hypersensitivity to any of the ingredients of ospemifene~2. Subject has used ospemifene in the past~3. Subject has documented or suspected breast cancer, history of heart attack or stroke~4. Subject has clinically significant findings on physical examination~5. Subject has uncontrolled hypertension~6. Subject has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study~7. Subject is currently on local or systemic androgen therapy including local or systemic testosterone (washout 14 days for local or topical androgen or non-depot injection, 1 month for depot, 6 months for pellet~8. Subject is currently on local or systemic estrogen therapy or androgen therapy (washout 14 days for vaginal estrogen, 60 days for oral/transdermal therapy)~9. Subject is currently using a Selective Estrogen Receptor Modulator (SERM) or products that have estrogenic or anti-estrogenic effects within last month~10. Subject currently using itraconazole, ketoconazole, digitalis or alkaloids heparin or strong cytochrome P 450 3A4 inhibitors~11. Subject has a history of substance abuse within 12 months prior, or consuming \> 14 alcoholic drinks per week~12. Subject has received an investigational drug within 30 days prior to signing consent~13. Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ospemifene open label (Type: EXPERIMENTAL): 60 mg ospemifene daily for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dailies Total 1 Sphere Contact Lenses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18-40~* Past contact lens wearers who have best corrected 20/20 visual acuity or better~* Participants will have had to have worn contact lenses for at least 1 year in the past~* Dropped out of contact lenses in the past 2 years do to discomfort or dryness~* Scores of 3 or less on the SPEED questionnaire~* Be able to be refit into Dailies Total1 Sphere contact lenses~* Provide a glasses prescription that is less than 3-years-old~Exclusion Criteria:~* Past rigid contact lens wearers~* A past history of being diagnosed with dry eye or ocular allergies~* Known systemic health conditions that are known to alter tear film physiology~* History of viral eye disease~* History of ocular surgery~* History of severe ocular trauma~* History of corneal dystrophies or degeneration~* Having active ocular infection or inflammation~* Currently using isotretinoin-derivatives or ocular medication~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Dailies Total1 (Type: EXPERIMENTAL): All participants will be asked to wear Dailies Total1 for the duration of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis (RA) per revised 1987 ACR criteria~* Active RA: ≥3 swollen and 3 tender joints with at least 1 swollen joint in the hand, excluding the PIP joint~* CRP \> 5.0 mg/L (RF and anti-CCP seronegative); CRP \>2 mg/l (RF and/or anti-CCP seropositive)~* DAS28 ≤ 5.1~* Stable regimen of concomitant RA therapy (NSAIDs, steroids, non- biological DMARDs).~* Negative PPD tuberculin skin test~Exclusion Criteria:~* Previous therapy with B or T cell depleting agents other than Rituximab (e.g. Campath). Prior treatment with Rituximab, TNF-inhibitors, other biologics (e.g. anti-IL-1 therapy) and systemic immunosuppressive agents is allowed with a washout period.~* Any history of ongoing, significant or recurring infections~* Any active inflammatory diseases other than RA~* Treatment with a systemic investigational drug within 6 months prior to screening~* Women of childbearing potential, unless receiving stable doses of methotrexate or leflunomide~* Significant cardiac or pulmonary disease (including methotrexate- associated lung toxicity)~* Hepatic or renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 0.3 mg/kg or placebo
- Group 2: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 1.0 mg/kg or placebo
- Group 3: MOR103, experimental (Type: EXPERIMENTAL): Biological: MOR103 1.5 mg/kg or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone for the Treatment of COVID-19 in Hospitalized Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Laboratory-confirmed COVID-19 with in 72 hours prior to randomization~2. Respiratory symptoms or abnormal lung exam or abnormal chest imaging AND oxygen saturation ≤94% on room air, or requiring supplemental oxygen less than 50% high flow~3. Understands and agrees to comply with planned study procedures~4. Agrees to the collection of venous blood per protocol~5. Must agree to be placed on prophylactic dose of anticoagulation for prevention of deep venous thrombosis (DVT) while hospitalized~Exclusion Criteria:~1. ALT or AST \>5 times the upper limit of normal~2. History of blood clots~3. History of breast cancer~4. Allergy to progesterone or betacyclodextrin~5. Use of supplemental oxygen prior to hospital admission~6. Requiring higher than 50% supplemental oxygen by high flow nasal cannula or mechanical ventilation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Progesterone plus SOC (Type: EXPERIMENTAL): Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
- SOC only (Type: NO_INTERVENTION): Subjects will receive institutional standard of care only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Atrial Fibrillation, Radiofrequency catheter ablation scheduled~Exclusion Criteria:~* Clinical trial denied

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous heparin infusion group (Type: ACTIVE_COMPARATOR): continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
- Intermittent heparin infusion group (Type: ACTIVE_COMPARATOR): Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Medical history of gastric and/or duodenal ulcer~* A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age~Exclusion Criteria:~* Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification~* History of esophageal, gastric or duodenal surgery~* Having severe liver disease or chronic renal disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 20 mg (Type: EXPERIMENTAL): Esomeprazole 20 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic palmoplantar plaque psoriasis (PPPsO) (with or without psoriatic arthritis) for at least 6 months before Baseline and a Palmoplantar Investigator's Global Assessment (ppIGA) of moderate or severe, at Screening and Baseline.~* Must have at Screening and Baseline a plaque psoriasis (PsO) body surface area (BSA) involvement of greater than or equal to one percent, an Static Physician's Global Assessment (sPGA) score of moderate to severe (greater than or equal to three), a PPASI moderate to severe (greater than or equal to eight), at least one additional PsO plaque outside of the palms and soles.~* Must be a candidate for systemic therapy as assessed by the investigator.~* Previously had inadequately controlled disease by topicals, phototherapy and/or systemic treatments.~Exclusion Criteria:~* History of PsO other than chronic plaque type PsO~* History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.~* Ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with PsO assessments.~* Evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV), Active tuberculosis, Active systemic infection/clinically important infections in the last two weeks prior to Baseline.~* Prior exposure to risankizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous placebo injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.
- Risankizumab (Type: EXPERIMENTAL): Participants received risankizumab 150 mg subcutaneous injections during the 16-week Double-blind Period at Baseline (Day 1) and Week 4. Starting at Week 16, all participants received open-label risankizumab 150 mg subcutaneous injections once every 12 weeks (q12w) at Weeks 16, 28, and 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete